TRCT
INDV icon

Tower Research Capital (TRC)’s Indivior Pharmaceuticals INDV Stock Holding History

Tower Research Capital (TRC)’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.3K Sell
995
-398
-29% -$13.1K ﹤0.01% 3158
2025
Q4 		$50K Sell
1,393
-1,811
-57% -$55.3K ﹤0.01% 2413
2025
Q3 		$77.2K Sell
3,204
-7,363
-70% -$154K ﹤0.01% 2197
2025
Q2 		$156K Buy
10,567
+9,456
+851% +$110K ﹤0.01% 2018
2025
Q1 		$10.6K Buy
1,111
+94
+9% +$988 ﹤0.01% 3623
2024
Q4 		$12.6K Buy
1,017
+712
+233% +$7.32K ﹤0.01% 3599
2024
Q3 		$2.97K Sell
305
-211
-41% -$2.47K ﹤0.01% 4915
2024
Q2 		$8.32K Sell
516
-3,022
-85% -$54.5K ﹤0.01% 4367
2024
Q1 		$75.8K Buy
+3,538
New +$66.5K ﹤0.01% 1994

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tower Research Capital (TRC)'s INDV Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Indivior Pharmaceuticals (INDV) stake by 29% in Q1 2026, selling an estimated $13.1K and leaving 995 shares worth $30.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3158.

Tower Research Capital (TRC) first reported a position in INDV in Q1 2024 and has held it in 9 quarters since. The position peaked at $156K in Q2 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Tower Research Capital (TRC) held 995 shares of Indivior Pharmaceuticals worth $30.3K as of Q1 2026.
  • Tower Research Capital (TRC) sold 398 Indivior Pharmaceuticals shares in Q1 2026, an estimated $13.1K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3158 holding.
  • Tower Research Capital (TRC) first reported a position in Indivior Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • Tower Research Capital (TRC)'s Indivior Pharmaceuticals position peaked at $156K in Q2 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.